About US
Contact us
-
FiercePharmaAsia—Teva’s China JV? Lupin plants’ roadblock, EOC’s $32M series BWelcome to this week's FiercePharmaAsia report, which includes stories about Teva's rumored Chinajoint venture, Lupin's regulatory hit that could hurt its U.S. sales, EOC Pharma's $32 million series B2017/11/10
-
Hikma FDA dispute lines Novartis' Sandoz up for Advair coupThose waiting for Hikma and Vectura’s copy of GlaxoSmithKline blockbuster Advair may be waiting awhile. After receiving a May rejection of the knockoff from the FDA, Hikma now says the partners are2017/11/10
-
Novartis breast cancer med Kisqali, struggling against Ibrance, finds niche in younger womenNovartis breast cancer med Kisqali has struggled to gain traction in a field dominated by Pfizer blockbuster Ibrance. So it’s branching out. Wednesday, the Swiss drugmakersaidthe med had nailed its2017/11/9
-
AstraZeneca executives try to shift I-O focus with China, Brilinta winsYou know executives are over the immuno-oncology questions when one of them offers to hand out a bottle of champagne to the first person to ask a question about cardiovascular, metabolic or respirator2017/11/9
-
IPEC-Americas and IPEC Europe Publish Co-Processed Excipient GuideIPEC-Americas and IPEC Europe Publish Co-Processed Excipient GuideIPEC-Americas and IPEC Europe have jointly published the Co-processed Excipient Guide for excipient makers and users. The new guide of2017/11/8
-
Alkermes balks at U.S. senator’s probe into 'aggressive' Vivitrol lobbying and marketingA basketful of opioid makers have been drawn into federal and state investigations into their marketing practices, but now one U.S. senator is going after a company that says it’s just trying to help2017/11/8
-
Allergan executives named in investor suit over alleged generics price fixingShortly after taking a beating over its Restasis tribal patent maneuver, Allergan is facing allegations that it betrayed shareholder interests by colluding to fix prices with other generic companies2017/11/7
-
Higher compliance & better patient outcomes? See how.Finding the right patient services model isn’t a simple task. Traditionally, rare disease manufacturers have been served by multi-channel models made up of disparate service providers, each claiming2017/11/7
-
Roche job cuts mount to 365 as drugmaker rethinks packagingJust hours after Roche confirmed that 130 workers will be cut from a California facility by year-end, the drugmaker said it will shave 235 jobs from a plant in Europe as it switches up how it handles2017/11/6
-
Potential costs to AmerisourceBergen from DOJ probe pile up to $575MTalk is cheap until it involves negotiations to settle a federal probe. That is the experience of wholesaler AmerisourceBergen, which now sees costs to resolve federal investigations into its sales of2017/11/6